Prolonged complete response after treatment withdrawal in HER2-overexpressed, hormone receptor-negative breast cancer with liver metastases: the prospect of disappearance of an incurable disease by Erika Viel et al.
Viel et al. BMC Cancer 2014, 14:690
http://www.biomedcentral.com/1471-2407/14/690CASE REPORT Open AccessProlonged complete response after treatment
withdrawal in HER2-overexpressed, hormone
receptor-negative breast cancer with liver
metastases: the prospect of disappearance of an
incurable disease
Erika Viel2*, Flavie Arbion1, Catherine Barbe1 and Philippe Bougnoux2Abstract
Background: Metastatic breast cancer has consistently been viewed as a non-curable disease. Specific palliative
treatments such as chemotherapy and hormone therapy have resulted in a mean overall survival of approximately
30 months. While cases of prolonged complete response have been reported with hormone or trastuzumab
monotherapy, rendering metastatic breast cancer a chronic disease, any treatment withdrawal has ineluctably led to
relapse. Prolonged remission without any anti-cancer treatment has never been reported to our knowledge.
Case presentation: We report here the unique observation of the spontaneous evolution of two breast cancer
patients with synchronous liver metastases who decided to stop trastuzumab after achieving complete response.
They were Caucasian women with synchronous liver metastatic breast carcinoma. Both breast cancers reached skin
and regional lymph nodes. There were several liver metastases in both patients. They received surgery, radiotherapy
and chemotherapy combined with trastuzumab. They decided to stop their treatment, despite guidelines. After a
follow-up longer than 20 months, they did not relapse clinically, radiologically, and biologically.
Conclusion: This findings question the belief of the unavoidability of recurrence of metastatic breast cancer,
specifically in the liver. It opens up the unprecedented possibility of a cure-like state in exceptional and probably
special cases.
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Metastatic breast cancer has consistently been consi-
dered as a non curable disease, which needs specific
palliative treatments in order to minimize symptoms
and allow patients to live with their disease [1]. With
systemic treatments such as chemotherapy and hormo-
nal therapy in patients whose tumor expresses steroid
hormone receptors, mean overall survival has been
ranging between 27.2 and 32.3 months [2,3]. The addition of
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unless otherwise stated.such as trastuzumab in patients with overexpression and/or
gene amplification of HER2 in tumors, has deeply modified
the evolution of the metastatic disease, leading to an increase
in OS (Overall Survival) to 37.6 month [4]. Even in visceral
metastases, such as liver metastases, where OS has been
particularly short when patients are not amenable to surgery
(19 to 26 months) [5] trastuzumab use has led to a dramatic
improvement, up to 32 months [6].
Prolonged complete responses have been reported in
steroid receptor positive metastatic breast cancer under
endocrine treatments. However, any interruption of this
endocrine treatment ineluctably leads to relapses. Similarly,
in steroid receptor negative, HER2 positive metastatic
breast cancer patients receiving anti-HER2 monotherapy,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Clinical features and evolution of patients. Loco-regional and systemic anti-cancer treatments of patients. Pathognomonic CT-scan
pictures of liver metastases at presentation (left), and complete response (right).
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remission and long-term survival [7,8], and for the same
reasons, it is thought that any interruption should lead to
relapses. In addition, guidelines presently recommend that
anti-HER2 treatments should be provided indefinitely, i.e.:
never interrupted as long as there is no toxicity or tumor
progression [9]. However, the main difference between the
two situations is that trastuzumab may have a cytotoxic
action, contrary to endocrine treatments [10,11]. This
potential cytotoxicity raises the question of the palliative
or curative nature of trastuzumab treatment, and to our
knowledge, a persistent complete response after total
discontinuation of trastuzumab has never been reported
in this setting.
We report here the cases of two patients with negative
steroid receptors, HER2-overexpressed breast carcinoma,
who presented with synchroneous liver metastases.
They received loco-regional and systemic treatments,
and achieved complete response. Contrary to recom-
mendations, they eventually decided to stop anti-HER2
treatment, and did not relapse. We report the unique
observation of their spontaneous evolution.
Case presentation
A 54-year-old woman and a 70-year-old woman were
referred to the Tours University Hospital Cancer Ward
with locally advanced breast cancer, a skin-connected
large breast cancer in one and an inflammatory breast






Figure 2 Pathological and immunohistochemical characterisation of t
tissue blocks. Haematoxylin and eosin staining (HES) confirmed invasive SB
(1D5, DAKO) and progesterone receptor (PgR 636 DAKO) branding compar
antibody (DAKO), a strong brown complete membrane staining was detecBoth had positive axillary lymph nodes. Several pathog-
nomonic images of synchronous liver metastases were
present on their CT-scans [12] (Figure 1). Pathology ana-
lysis of the breast tumors (biopsy or surgery) confirmed
invasive ductal carcinomas, with a SBR grade of 3, nega-
tive for steroid receptors but HER2-positive on immuno-
histochemistry (Figure 2). Both patients had a mastectomy
and a minimal axillary lymph node resection as several
reports suggest that locoregional treatment of the pri-
mary tumor improves outcome in women with stage IV
breast cancer at diagnosis [13,14]. The first patient had
a hemorrhagic tumor, and the second patient required a
rapid complete locoregional treatment subsequent to
induction chemotherapy. Both patients had radiation
therapy of the chest wall. This included the supra cla-
vicular area for the second patient (Figure 1).
The first patient received 8 cycles of docetaxel (100 mg/
m2) combined with trastuzumab (6 mg/kg every 3 weeks).
Trastuzumab was continued as maintenance therapy.
Complete response was obtained in the liver 23 months
after diagnosis. She decided to cease taking trastuzumab
after 50 months of treatment. At 30 months’ follow-up
after withdrawal of trastuzumab, she remains in complete
response biologically and radiologically (Figure 1).
The second patient received 4 cycles of epirubicin-
containing chemotherapy (FEC 100 regimen), then 2 cycles
of docetaxel (100 mg/m2) combined with trastuzumab
(6 mg/kg every 3 weeks). Complete response was docu-




umors. Pathologic analyses were performed on paraffin-embedded
R3 carcinomas. No staining was detected after estrogen receptor
ed to positive and negative controls. Using the A485 polyclonal
ted in more than 30% tumor cells in both patients.
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sponse of liver metastases at the time of breast surgery.
Trastuzumab maintenance followed this induction treat-
ment. Complete liver response was achieved after 7 months’
trastuzumab maintenance, i.e.: 1 year after diagnosis.
The patient decided to stop trastuzumab treatment after
24 months of maintenance. She has not received any
specific anti-cancer treatment for 42 months, and still
displays a complete biological and radiological response
(Figure 1).
In HER2-overexpressed metastatic breast cancer, me-
dian OS has been reported to be close to 25 months,
and median time to progression (TTP) approximately
12.4 months [7], despite the use of specific treatments.
In our two cases, although all treatment had been
withdrawn for 30 and 42 months, no relapse occurred.
This appears quite remarkable and raises the question of
the already suggested [15] possible eradication of these
presentations of metastatic breast cancer as a conse-
quence of the medical treatment.
It is not known whether these results might be specific
to this type of cancer, i.e.: HER2-overexpressed, steroid
receptor-negative breast carcinoma, as already evoked
[15], since this has never been reported with other
pathological features. This case-report is not intended to
establish whether a cause-and-effect relationship exists
between those excellent clinical results and trastuzumab
administration. One should wonder if the theoretical
cytotoxicity of trastuzumab might potentially lead to
disappearance or dormancy of any cancer clone, the
commonly accepted cause of relapse [16].
Conclusions
Other similar cases may not have been identified to date
because of current guidelines [8]. This short paper may
generate other reports which may allow the constitution
of a cohort of similar cases. Predicting among patients
in complete response which patients are most likely to
do well after trastuzumab withdrawal remains a challenge.
Finally, the present situation raises questions regarding
the belief in the unavoidability of recurrence of metastatic
breast cancer, specifically in the liver. It opens up the
unprecedented possibility of a cure-like state in exceptional
cases.
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